

# **Order Form for High Risk Vaccine** One form per client

Name of Client:		Date of Birth:	Age:	
			YYYY/MM/DD	
Gender:	Ontario Health Card Number	:	HCP Phone Number:	
🗆 Male 🗆 Female 🗆 Other				
Health Care Practitioner Name (HCP):		HCP Fax Number:		
Facility Name: HCP and/		or Designate Signature:		
Date of Request: YYYY/	MM/DD			
Date of scheduled appointment: YYYY/MM/DD				

Please note, you must complete and fax this form immediately to the Porcupine Health Unit in Timmins at 705-360-7308 once the vaccine is administered. (You will receive a copy of this form with the vaccine for you to fax.)

Vaccine Administration				
Date Administered:	Site Administered:	Type of Vaccine:	Lot #	
YYYY / MM / DD			Expiry Date:	
Date Administered:	Site Administered:	Type of Vaccine:	Lot #	
YYYY / MM / DD			Expiry Date:	

\*For each vaccine being requested, check all criteria(s) that apply for this client:

Haemophilus infuenzae type b - Act-Hib® (6571-3255-0)	Dose being requested:  Dose 1 Dose 2 Dose 3
Eligibility - ≥ 5 years with:	<ul> <li>Bone marrow or solid organ transplant recipient (1 dose)</li> </ul>
Hematopoietic stem cell transplant recipient (HSCT) *(3 doses)	Lung transplant recipient (1 dose)
<ul> <li>Functional or anatomic asplenia (1 dose)</li> <li>Immunocompromised related to disease or therapy (1 dose)</li> </ul>	<ul> <li>Cochlear implant recipient (pre/post implant) (1 dose)</li> <li>Primary antibody deficiency (1 dose)</li> </ul>

# Meningococcal B - Bexsero<sup>®</sup> (6571-3314-0) Dose being requested: Dose 1 Dose 2 Dose 3 Dose 4

#### Eligibility – Age 2 months to 17 years with:

Functional or anatomic asplenia

□ Complement, properdin, factor D deficiency, or primarily antibody deficiency

□ Cochlear implant recipient (pre/post implant)

□ Those born in 2002, 2003, 2004 or 2005 (eligible until December 31, 2023)

□ Acquired complement deficiency (e.g., receiving eculizumab)

□ HIV

Meningococcal C-ACYW135 Dose being requested: Dose 1 Dose 2 Dose 3 Dose 4 Booster

 $\Box$  Nimenrix<sup>®</sup> (6571-3370-0) <u>2 to 55 years</u> or <u>> 56 years of age to replace menomune</u>

□ **Menveo<sup>®</sup>** (6571-2017-0) 9 to 23 months of age

### Eligibility - 9 months to 55 years or ≥ 56 years

Functional or anatomic asplenia

□ Complement, properdin, factor D deficiency, or primarily antibody deficiency

□ Cochlear implant recipient (pre/post implant)

□ Acquired complement deficiency (e.g., receiving eculizumab)

□ HIV

Hepatitis A (Avaxim <sup>®</sup> /Havrix <sup>®</sup> /VAQTA <sup>®</sup> )	Dose being requested:  Dose 1 Dose 2
□ adult (6571-3257-0) □ paediatric (6571-3256-0)	
Eligibility – $\geq$ to 1 year with:	Persons engaging in intravenous drug use

□ Chronic liver disease (including Hepatitis B and C)

Men who have sex with men

# **Order Form for High Risk Vaccine** One form per client

One form per client				
Human Papillomavirus Vaccine - Gardasil9 <sup>®</sup> (6571-3390-0)	Dose being requested:  Dose 1 Dose 2 Dose 3			
Eligibility - ≤ 26 years of age who have <u>NOT</u> started a series already and who are: □ males born in 1993, 1994, 1995, 1996 or 1997 (eligible until December 31, 2024) □ men who have sex with men (MSM), including gay, bisexual and trans (those who identify as MSM)				
	sted:  Dose 1 Dose 2 Dose 3 Dose 4 (for premature babies ONLY)			
□ paediatric (6571-3251-0) □ adult/adolescent 20 mcg (6	571-3243-0) 🛛 renal dialysis 40 mcg (6571-3324-1)			
<ul> <li>Eligibility - ≥ to 0 years of age:</li> <li>Infant born to HBV-positive carrier mothers:</li> <li>Premature infant weighing &lt;2000 grams at birth (4 doses)</li> <li>Premature infant weighing ≥2000 grams at birth and full/post</li> <li>Household or sexual contact of chronic carrier or acute case (3 doses)</li> <li>Awaiting liver transplant (2<sup>nd</sup> and 3<sup>rd</sup> doses only)</li> <li>Men who have sex with men, individual with multiple sex partners, of</li> <li>Needle stick injury in a non-health care setting (3 doses)</li> <li>Child &lt;7 years old whose family has immigrated from country of high hepatitis B carriers through their extended family (3 doses)</li> <li>Renal dialysis or disease requiring frequent receipt of blood products</li> <li>Individual engaging in intravenous drug use (3 doses)</li> <li>Chronic liver disease including hepatitis C (3 doses)</li> </ul>	) or history of a sexually transmitted disease (3 doses) a prevalence for hepatitis B and who may be exposed to s (eg., haemophilia) (2 <sup>nd</sup> and 3 <sup>rd</sup> doses only)			
Pneumococcal C-20 Valent – Prevnar-20 <sup>®</sup> (6571-4010-2)	Dose being requested:  Dose 1			
<ul> <li>Use existing inventory if you have it and if the client meets criteria below</li> <li>** Please refer to following HCP Fact Sheets for guidance on product to use, number of doses required, intervals and how to complete a vaccine series when other Pneumococcal products were used.</li> <li>HCP Fact Sheet: Pneumococcal conjugate vaccine for individuals aged 5-64 years at high risk for IPD for vaccine intervals.</li> <li>HCP Fact Sheet: Pneumococcal conjugate vaccines for children aged 6 weeks to 4 years.</li> </ul>				
<ul> <li>Asplenia (anatomical or functional), splenic dysfunction</li> <li>Congenital (primary) immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions.</li> <li>HIV infection</li> <li>Immunocompromising therapy including use of long-term systemic corticosteroid, chemotherapy, radiation therapy, post-organ</li> </ul>	<ul> <li>Chronic renal disease, including nephrotic syndrome</li> <li>Chronic cardiac disease</li> <li>Chronic liver disease, including hepatitis B and C</li> <li>Chronic respiratory disease, excluding asthma, except those treated with high-dose corticosteroid therapy</li> <li>Chronic neurologic conditions that may impair clearance of oral secretions</li> <li>Diabetes mellitus</li> </ul>			

- Diabetes mellitus
- □ Cochlear implant recipients (pre/post implant)
- □ Chronic cerebral spinal fluid leak
- Residents of nursing homes, homes for the aged and chronic care facilities or wards
- □ Hematopoietic stem cell transplant (HSCT) (recipient)

Adverse Event Following Immunization (AEFI): Remember to report any AEFI's to the Porcupine Health Unit

transplant therapy, certain anti-rheumatic drugs and other

□ Malignant neoplasms, including leukemia and lymphoma

□ Solid organ or islet cell transplant (recipient)

□ Sickle-cell disease and other sickle cell hemoglobinopathies

immunosuppressive therapy

□ Hepatic cirrhosis due to any cause